alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
UNPUBLISHED
UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT

No. 21
- 7051

UNITED STATES OF AMERICA, Plaintiff

- Appellee ,

v. REGINALD ANTHONY FALICE , Defendant

- Appellant

.

Appeal from the United States District Court for the Western District of North Carolina , at Charlotte

. Graham C. Mullen, Senior District Judge. ( 3:98

- cr - 00244

- GCM

- 1 )

Submitted : October 14, 2021 Decided: October 19, 2021

Before DIAZ and QUATTLEBAUM, Circuit Judges, and KEENAN, Senior Circuit Judge.
Dismissed by unpublished per curiam opinion

. Reginald Anthony Falice , Appellant Pro Se.
Unpublished opinions are not binding precedent in this circuit.2 PER CURIAM:
Re ginald Anthony Falice seeks to appeal the district court’s order denying his motion to vacate his conviction and sentence. We conclude that Falice ’s motion was in substance a successive 28 U.S.C. § 2255 motion. The order denying the motion is not appealable unless a circuit justice or judge issues a certificate of appealability. See 28 U.S.C. § 2253(c)(1)(B). A certificate of appealability will not issue absent “a substantial showing of the denial of a constitutional
ri ght.” 28 U.S.C. § 2253(c)(2). When the district court denies relief on the merits, a prisoner satisfies this standard by demonstrating that reasonable jurists could find the district court’s assessment of the constitutional claims debatable or wrong. Se e Buck v.
Davis , 137 S. Ct. 759, 773

- 74 (2017). When the district court denies relief on procedural grounds, the prisoner must demonstrate both that the dispositive procedural ruling is debatable and that the motion states a debatable claim of the denial of a constitutional right. Gonzalez v. Thaler , 565 U.S. 134, 140

- 41 (2012) (citing Slack v. McDaniel , 529 U.S. 473, 484 (2000)). We have independently reviewed the record and conclude that Falice has not made the requisite showing. The claims Falice r aised in his motion challenged the validity of his conviction and sentence, and, thus, the motion should have been construed as a successive § 2255 motion. * See Gonzalez v. Crosby , 545 U.S. 524, 531

- 32 (2005); United States v.
McRae , 793 F.3d 392, 397

- 99 (4th Cir. 2015). Absent prefiling authorization from this

* The district court denied relief on Falice’s prior § 2255 motion in 2003.3 court, the district court lacked jurisdiction to entertain Falice ’s successive § 2255 motion.
See 28 U.S.C. §§ 2244(b)(3), 2255(h). Accordingly, we deny a certificate of appealability and dismis s the appeal. We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before this court and argument would not aid the decisional process.
DISMISSED
수면 문제

미식품의약국 (FDA) 여성 보건 부서

www.fda.gov/womens

수면에 관한 기본 지식

대부분 성인은 매일 밤 7-8 시간의 수면이 

필요합니다. 모든 사람들이 필요한 수면을 취하는 

것은 아닙니다. 

때때로 다음과 같은 이유로 수면에 장애를 받을 수 

있습니다:

• 스트레스

• 건강 문제와 약

• 장시간 일함/교대 근무

• 빛 혹은 소음

• 음주 혹은 잠 자는 시간 가깝게 음식 섭취

대부분 밤에 잠 들거나 계속 잠 들어 있지 못하다면 

불면증이라는 수면 장애가 있을 수 있습니다.

어떤 사람들은 더욱 심각한 수면 장애를 

가지고 있습니다. 다음에 해당하면 담당 의사와 

상의하십시오:

• 낮에 잠에 든다

• 잠 자는 동안 코를 골거나 숨이 막히는 소리를 낸다

• 다리에 이상한 느낌이 들거나 다리를 움직일 

필요를 느낀다

수면에 도움이 되는 약

잠에 들도록 도움을 주거나 계속 잠을 잘 수 있도록

도움을 주는 약들이 있습니다. 어떤 수면제는 의사의 

처방이 필요합니다. 처방 없이 구입 가능한 다른 

약들도 있습니다.

처방약

처방 수면제는 많은 사람들에게 잘 듣지만 심각한 

부작용을 일으킬 수 있습니다.

• 처방 수면제 사용에 대한 모든 위험과 이점에 

대하여 담당 의사와 상의하십시오. 

• 불면증에 대하여 사용된 수면제는 사용 다음날 

아침 운전에 영향을 미칠 수 있습니다.

• 수면제는 다음과 같은 드문 부작용을 일으킬 수 

있습니다:

- 심각한 알러지 반응

- 심각한 얼굴 부종

- 완전히 깨어 있지 않은 상태에서 전화하고, 먹고, 

성관계를 하거나 운전함

처방 없이 구입 가능한 약 (OTC)

처방 없이 구입 가능한 약도 부작용이 있습니다. “약 

정보지” 표시를 읽고 처방 없이 구입 가능한 수면제의 

부작용에 대하여 배우십시오. 
 이 정보지는 미식품의약국 (FDA) 여성 보건 부서에서 제작되었습니다. 

다른 여성 보건 관련 정보를 얻기 위해서는 다음을 방문해 주십시오

www.fda.gov/womens

2021

수면 문제

더 나은 수면을 위한 조언

저녁 시간의 습관들에 변화를 주면 필요한 수면을 취하는데 도움을 받을 수도 있습니다. 

• 매일 같은 시간에 자고 같은 시간에 일어나십시오. 

• 어둡고 조용한 방에서 수면을 취하십시오. 

• 카페인과 니코틴을 피하십시오

• 잠 들기 전에 술을 마시지 마십시오. 

• 잠 들기 전 휴식을 취하게 해주는 것들을 하십시오. 

• 잠 들기 전 운동하지 마십시오. 

• 오후 3시 이후 낮잠을 취하지 마십시오. 

• 잠 들기 전 많이 음식을 섭취하지 마십시오. 

이주 이상 매일 밤 수면 장애가 있을 경우 담당 의료 제공자와 

상담하십시오.

수면 문제 (KOREAN)
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 95-7877

UNITED STATES OF AMERICA,

Plaintiff - Appellee,

versus

PASCUAL RUIZ,

Defendant - Appellant.

Appeal from the United States District Court for the Southern

District of West Virginia, at Charleston. John T. Copenhaver, Jr.,

District Judge. (CR-93-108; CA-95-357-2)

Submitted: April 4, 1996 Decided: May 20, 1996

Before NIEMEYER and WILLIAMS, Circuit Judges, and BUTZNER, Senior

Circuit Judge.

Affirmed by unpublished per curiam opinion.

Pascual Ruiz, Appellant Pro Se. Rebecca A. Betts, United States

Attorney, Charleston, West Virginia, for Appellee.

Unpublished opinions are not binding precedent in this circuit. See

Local Rule 36(c).
2

PER CURIAM:

Appellant appeals from the district court's order denying his

28 U.S.C. § 2255 (1988) motion. We have reviewed the record and the

district court's opinion accepting the recommendation of the

magistrate judge and find no reversible error. Accordingly, we

affirm on the reasoning of the district court. United States v.

Ruiz, Nos. CR-93-108; CA-95-357-2 (S.D.W. Va. Sept. 22, 1995). We

dispense with oral argument because the facts and legal contentions

are adequately presented in the materials before the court and

argument would not aid the decisional process.

AFFIRMED
Presidential Documents

Federal Register / Vol. 60, No. 87 / Friday, May 5, 1995 / Presidential Documents 22449

Presidential Determination No. 95–19 of April 21, 1995

Determination Under Section 2(b)(2)(D) of the Export-Import

Bank Act of 1945, as Amended: People’s Republic of China

Memorandum for the Secretary of State

Pursuant to Section 2(b)(2)(D) of the Export-Import Bank Act of 1945, as

amended, I determine that it is in the national interest for the ExportImport Bank of the United States to extend a loan in the amount of approximately $278,120,000 to the People’s Republic of China in connection with

the purchase of U.S. equipment and services for the construction of a power

plant in Dandong, Liaoning Province.

You are authorized and directed to report this determination to the Congress

and publish it in the Federal Register

œ–.

THE WHITE HOUSE,

Washington, April 21, 1995. [FR Doc. 95–11340

Filed 5–4–95; 9:43 am]

Billing code 4710–10–M
Harold J. THORNTON, petitioner, v. Richard IVES, Warden.

No. 12-6608.

Supreme Court of the United States

June 10, 2013.

Petition for rehearing denied.
Pacino Duval NEELY, petitioner, v. FLORIDA.

No. 12-8734.

Supreme Court of the United States

April 15, 2013.

Petition for writ of certiorari to the Supreme Court of Florida denied.
Amendment to the Excess Contribution Plan



 Exhibit 10(v) 
  
 AMENDMENT TO THE BANK OF NEW YORK COMPANY, INC. 
 EXCESS CONTRIBUTION PLAN 
  
 WHEREAS, The Bank of New York Company, Inc. Excess Contribution Plan (the “Excess Contribution Plan”) was amended and restated, effective as of July 10, 1990; and 
  
 WHEREAS, Section 19 of the Excess Contribution Plan provides that the Board of Directors of The Bank of New York Company,
Inc. may amend the Excess Contribution Plan at any time; except in certain respects not material hereto; and 
  
 WHEREAS, the Board of Directors of the Company desires to amend the Excess Contribution Plan; 
  
 NOW, THEREFORE, the Excess Contribution Plan is hereby amended, effective as
of November 12, 2002, by amending the second sentence of Section 4 to read as follows: 
  
 When a Participant’s benefit payments under the ESOP commence (or when his benefits under the ESOP are transferred to the Retirement
Plan of The Bank of New York Company, Inc.), a Participant shall receive payment, in cash, of the excess, if any, of (i) the equivalent actuarial value of the Stock Units credited to the Participant’s Account, expressed as a life annuity, and
(ii) the benefit to which the Participant is entitled to receive under Part I of The Bank of New York Company, Inc. Excess Benefit Plan. 
  
 IN WITNESS WHEREOF, The Bank of New York Company, Inc. has caused this Amendment to be executed by its duly authorized officers this 22th day of January,
2002. 
  
 /s/    Thomas
A. Renyi 
         Thomas A. Renyi 
  
 ATTEST: 
  
 /s/    Patricia A. Bicket 
         Patricia A. Bicket 
  

 -1-
[DO NOT PUBLISH]

IN THE UNITED STATES COURT OF APPEALS

FOR THE ELEVENTH CIRCUIT

________________________

No. 20-14506

Non-Argument Calendar

________________________

D.C. Docket No. 8:10-cr-00252-JSM-TBM-1

UNITED STATES OF AMERICA, 

 Plaintiff-Appellee,

 versus

VICTOR HUGO BRAVO ARMENDARIZ, 

 Defendant-Appellant.

________________________

Appeal from the United States District Court

for the Middle District of Florida

________________________

(July 13, 2021)

Before MARTIN, BRANCH and LUCK, Circuit Judges.

PER CURIAM:

USCA11 Case: 20-14506 Date Filed: 07/13/2021 Page: 1 of 2
2

Stephen Langs, appointed counsel for Victor Armendariz in this appeal of 

the revocation of Armendariz’s supervised release and sentence imposed upon 

revocation, has moved to withdraw from further representation of the appellant and 

filed a brief pursuant to Anders v. California, 386 U.S. 738 (1967). Our 

independent review of the entire record reveals that counsel’s assessment of the 

relative merit of the appeal is correct. Because independent examination of the 

entire record reveals no arguable issues of merit, counsel’s motion to withdraw is 

GRANTED, and Armendariz’s revocation of supervised release and sentence

imposed upon revocation are AFFIRMED.

USCA11 Case: 20-14506 Date Filed: 07/13/2021 Page: 2 of 2
[Federal Register Volume 60, Number 90 (Wednesday, May 10, 1995)]
[Notices]
[Page 24851]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-11506]



-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY
[FRL-5205-1]


Correction to Previous Notice of Contractor Access to 
Confidential Business Information Under the Clean Air Act

AGENCY: Environmental Protection Agency (EPA).

ACTION: Correction.

-----------------------------------------------------------------------

SUMMARY: On April 17, 1995, the EPA published a Federal Register Notice 
announcing contractor access to confidential business information (60 
FR 19250). This notice incorrectly listed contract numbers and contract 
expiration dates. The correct information is as follows.
    The EPA has authorized the following subcontractors for access to 
information that has been, or will be, submitted to EPA under section 
114 of the Clean Air Act (CAA) as amended. (1) EC/R, Inc., 3721-D 
University Drive, Durham, NC 27707, contract number 68D10118; (2) Alpha 
Gamma Technologies, Inc., 900 Ridgefield Drive, Suite 350, Raleigh, NC 
27609, contract number 68D10117; (3) Energy and Environmental Research 
Corporation (EER), 3710 University Drive, Suite 160, contract 68D10117. 
The prime contractor for contract 68D10117 is Radian Corporation, PO 
Box 13000, RTP, NC 27709 and the prime contractor for contract 68D10118 
is Research Triangle Institute, PO Box 12194, RTP, NC 27709. Both of 
these contracts expire on August 1, 1996, thus CBI access under these 
contracts expires at that time as well.

DATES: Access to confidential data submitted to EPA will occur no 
sooner than ten days after issuance of this notice.

FOR FURTHER INFORMATION CONTACT: Doris Maxwell, Document Control 
Officer, Office of Air Quality Planning and Standards (MD-13), U.S. 
Environmental Protection Agency, Research Triangle Park, North Carolina 
27711, (919) 541-5312.

    Dated: May 1, 1995.
Richard D. Wilson,
Acting Assistant Administrator for Air and Radiation.
[FR Doc. 95-11506 Filed 5-9-95; 8:45 am]
BILLING CODE 6560-50-P
Donald DAVIS, petitioner, v. UNITED STATES.

No. 12-10068.

Supreme Court of the United States

June 3, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Fifth Circuit denied.
```
[Federal Register Volume 60, Number 82 (Friday, April 28, 1995)]
[Notices]
[Page 21023]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-10446]

-----------------------------------------------------------------------

DEPARTMENT OF THE TREASURY
[T.D. 95-39]

License Cancellations

AGENCY: U.S. Customs Service, Department of the Treasury.

ACTION: General notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that, pursuant to 19 CFR 111.51(a), the 
following Customs broker licenses have been cancelled due to the death 
of the broker. These licenses were issued in various Customs Districts.

Alfred J. Stanoch
 license no. 3407
Raymond Hemerich
 license no. 4752

    Dated: April 24, 1995.
Philip Metzger,
 Director, Trade Compliance.
[FR Doc. 95-10446 Filed 4-27-95; 8:45 am]
BILLING CODE 4820-02-P
```
Chết Chỉ Vì Món Salad?

Một ngày nọ, tôi phải làm cả hai việc cùng một lúc.Tôi chuẩn bị thịt...

... rồi lại cắt rau diếp bằng chính cái thớt đó chứ không rửa và vệ sinh thớt đúng cách trước.

Chỉ vì tôi không rửa, tráng và vệ sinh thớt mà 20 khách hàng đã bị bệnh nặng, một ngưtử vong, và nhà hàng của chúng tôi đã phải đóng cửa.

Hãy Bảo Vệ Mọi Người Ở Mọi Nơi. Luôn Rửa, Tráng, VThiết Bị và Vật Dụng Giữa Các Lần Sử Dụng.
Office of Global Policy and Strategy 

OGPS STATEMENT: Celebrating Locally Employed Staff Recognition Day

1RYHPEHU 1, 2022 

Dear Colleagues, 

Today, we celebrate the 2022 Foreign Service National (FSN) and Locally Employed (LE Staff) 

Recognition Day. The words of an experienced overseas OGPS leader put it best: “Our locally 

employed staff are the folks who really know how work gets done in their countries and 

cultures. They really make the world turn out here!” 

On my recent visits to the Latin America, India, and Europe offices, I saw firsthand how vital our 

local staff are to the OGPS mission. It was apparent to me, as it is to all of OGPS leadership, that 

the local staff have a keen knowledge of FDA relations in-country with host government 

officials; that they provide the technical knowledge of local systems, maintain valuable contacts

with in-country stakeholders, and provide critical administrative support that helps our foreign 

offices function efficiently and effectively. 

I hope you all will take a moment today and consider the valuable contributions of our locally 

employed staff serving all over the world. 

With sincerest appreciation, 

Mark Abdoo

Associate Commissioner for Global Policy & Strategy
이 문서는 미식품의약국 (FDA)의 

여성보건부서 (OWH)와 전국 체인 약국 

연합 (NACDS)에 의하여 제작되었습니다. 

약을 사용하는 사람들의 30%에서 50%

는 지시 받은 대로 약을 사용하지 

않습니다. 이것은 더 많은 의사 방문, 

입원, 급여 손실, 그리고 처방 변경을 

초래합니다. 이 비용은 매년 천억 이상이 

듭니다. 

성인들은 종종 자신뿐만 아니라 온 

가족의 약을 관리합니다. 그리므로 

상표를 읽고, 문제를 피하고, 질문하고, 

기록해야 합니다. 

1. 상표를 읽으십시오

약을 복용하기 전에 상표를 읽으십시오. 

상표는 다음 사항들을 표시합니다:

성분 목록 - 약에 들어 있는 성분에 

알러지가 있다는 것을 알면 약을 

사용하지 마십시오. 의사나 약사에게 

다른 약을 요청하십시오..

경고 -주의해서 읽으십시오.

유통 기간 – 약병에 적혀있는 날짜가 

지났으면 약을 사용하지 마십시오. 잘 

듣지 않을 수 있습니다..

약에 대한 더 많은 정보를 얻기 

위해서는 약사에게 문의하십시오.

2. 문제를 피하십시오

약은 졸음, 구토, 출혈, 두통, 혹은 

발진과 같은 부작용을 초래할 수 

있습니다. 복용하는 약의 부작용에 

대하여 문의하십시오. 담당 의사, 약사, 

혹은 간호사와 상담하십시오.

약을 정리하십시오.

약을 빠지지 말고 드십시오.

약을 공유하지 마십시오.

어두운 곳에서 약을 드시지 마십시오.

약을 지혜롭게 사용하십시오 

스스로를 돌보고 ... 귀하를 필요로 하는 사람들을 돌보십시오

시간을 들여 돌보십시오

여성 보건부서 

www.fda.gov/womens

시간을 들여 돌보십시오

스스로를 돌보고...귀하를 필요로 하는 사람들을 돌보십시오

내가 복용하는 약들
3. 질문 하십시오

• 약 이름은 무엇입니까?

• 일반적인 이름의 약이 사용 가능합니까?

• 왜 이 약을 복용합니까?

• 언제 약을 복용해야 합니까?

• 빈 속에 아니면 음식과 같이 복용해야

 합니까?

• 술과 같이 복용해도 안전합니까?

• 잊고 못 복용했으면 어떻게 해야

 합니까?

• 얼마나 복용해야 합니까?

• 얼마나 오래 동안 복용해야 합니까?

• 어떤 문제들에 주의해야 합니까?

임신했거나 모유 수유중이면 약이나 

보조제를 복용하기 전에 의료 전문가의 

조언을 들으십시오. 담당 의사, 약사, 혹은 

간호사와 상담하십시오. 기꺼이 그분들이 

도와줄 겁니다. 

알러지 목록

의사

전화 번호 

4. 귀하가 사용하는 약 목록을

보관하십시오

사용하는 것에 체크하십시오:

아스피린이나 다통증/두통

/발열 약

알러지약

제산제

감기약

기침약

살빼는 약/보조제 

변비약

수면제 

비타민 

미네랄 

허브

그외

이 내용을 지갑이나 주머니에 보관하여 담당 의사, 약사, 혹은 간호사에게 보여 주십시오.

이름:

처방약 목록

날짜 내 약 이름

얼마나 

복용합니까 언제 복용합니까 무엇에 복용하는 

약입니까 다시 약병을 채움

 예 XXXX 1 정 400 

밀리그램(mg) 식후 하루 3회 관절염 2

담당 의사, 약사, 혹은 간호사가 심각한 약 문제를 미식품의약국 (FDA) 1-800-FDA-1088로 신고하도록 하십시오.
Dennis Lenard BROWN, petitioner, v. FLORIDA.

No. 12-8273.

Supreme Court of the United States

April 15, 2013.

Petition for writ of certiorari to the District Court of Appeal of Florida, Fifth District, denied.
Peter J. HONESTO, petitioner, v. James D. HARTLEY, Warden.

No. 12-8601.

Supreme Court of the United States

April 15, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Ninth Circuit denied.
David MURPHY, petitioner, v. UNITED STATES.

No. 12-9352.

Supreme Court of the United States

April 22, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Second Circuit denied.
ITACS FACT SHEET

JANUARY 2023

ITACS (Import Trade 

Auxiliary Communication

System) basic functionality 

was released in August 2011 

and provides the import trade 

community with four 

functions: the ability to check 

the status of FDA- regulated 

entries and lines, the ability to 

submit entry documentation 

electronically, the ability to 

electronically submit the 

location of goods availability 

for those lines targeted for 

FDA exam, and the ability to 

check the estimated laboratory 

analysis completion date for 

sampled lines.

Documents may be submitted 

as PDF files as well as other 

common file and picture types 

including Microsoft Word 

documents and jpeg files. 

When submitting availability 

of goods for examination, 

the user may either indicate 

that the goods are located at 

the consignee as filed in the 

FDA entry, or at another 

location as entered by the 

user. 

ITACS basic functionality 

may be accessed via the web 

at https://itacs.fda.gov. No 

login accounts are necessary. 

All that is needed is a valid 

Customs entry number that 

has been successfully 

transmitted to FDA.

Note that review of 

documents submitted to FDA 

via ITACS is prioritized over 

review of documents 

submitted to FDA via other 

means. 

ITACS Account Management 

functionality was released in 

September 2017 and enables the 

electronic distribution of 

Notices of FDA Action via 

email and as downloads from 

within ITACS. It also allows 

account holders to view the 

details of specific information 

requests, which are currently 

delivered via hard copy Notices 

of FDA Action. ITACS 

Account Management 

functionality may be used by 

Filers, Importers of Record and 

Consignees with an approved 

ITACS account. To be granted 

an account a firm must have 

been a party to a previously 

transmitted FDA entry.

ITACS accounts are limited to 

one individual per firm at the 

corporate level. This person 

should be a high-ranking 

individual within the firm as 

they will have the responsibility 

to create and manage ITACS 

accounts for other users within 

their firm.

ITACS accounts can be 

requested via the FDA Unified 

Registration and Listing System

(FURLS) at 

https://www.access.fda.gov/oaa/

Use of ITACS offers several 

benefits to the Import Trade 

Community as well as to FDA, 

including more detailed FDA 

entry/line statuses than what is 

currently transmitted to filers via 

CBP systems reducing the need 

for phone calls inquiring about 

entry status, eliminating the need 

to email or fax entry 

documentation and goods 

availability to FDA, and no 

problems with lost documents. 

Benefits of ITACS accounts 

include faster receipt of Notices 

of FDA Action via email or 

download in ITACS, no need to 

maintain paper copies of Notices 

of FDA Action as they will 

continue to be available in 

ITACS even after an entry is 

closed and faster receipt of 

requests for specific information 

by email or ITACS.

For questions about ITACS as 

well as to report problems and 

suggest improvements, please 

contact us at 

itacssupport@fda.hhs.gov
Clarence E. BROWN, petitioner, v. WISCONSIN.

No. 12-8746.

Supreme Court of the United States

April 29, 2013.

Petition for writ of certiorari to the Court of Appeals of Wisconsin, District I, denied.
Exhibit 31**CERTIFICATION**I, Ted L. Hall, certify that:     1. I have reviewed this quarterly report on Form 10-Q of Kiewit Royalty Trust, for which U.S.Bank National Association acts as Trustee;     2. Based on my knowledge, this quarterly report does not contain any untrue statement of amaterial fact or omit to state a material fact necessary to make the statements made, in light ofthe circumstances under which such statements were made, not misleading with respect to the periodcovered by this quarterly report;     3. Based on my knowledge, the financial statements, and other financial information includedin this quarterly report, fairly present in all material respects the financial condition,distributable income and changes in trust corpus of the registrant as of, and for, the periodspresented in this quarterly report;     4. I am responsible for establishing and maintaining disclosure controls and procedures (asdefined in Exchange Act Rules 13a-15(e) and 15d-15(e)), or for causing such procedures to beestablished and maintained, for the registrant and I have:     a) designed such disclosure controls and procedures, or caused such controls and procedures tobe designed under my supervision, to ensure that material information relating to the registrant ismade known to me by others within the registrant, particularly during the period in which thisquarterly report is being prepared;     b) evaluated the effectiveness of the registrant’s disclosure controls and procedures andpresented in this report my conclusions about the effectiveness of the disclosure controls andprocedures as of the end of the period covered by this report, based on my evaluation; and     c) disclosed in this report any change in the registrant’s internal control over financialreporting that occurred during the registrant’s most recent fiscal quarter that has materiallyaffected, or is reasonably likely to materially affect, the registrant’s internal control overfinancial reporting; and     5. I have disclosed, based on my most recent evaluation, to the registrant’s auditors:     a) all significant deficiencies and material weaknesses in the design or operation of internalcontrol over financial reporting which are reasonably likely to adversely affect the registrant’sability to record, process, summarize and report financial information; and     b) any fraud, whether or not material, that involves management or other employees who have asignificant role in the registrant’s internal control over financial reporting.     In giving the certifications in paragraphs 4 and 5 above, I have relied to the extent Iconsider reasonable on information provided to me by Amber Brewster, Bank of Oklahoma.Date: July 28, 2005/s/ Ted L. Hall